Ratings
0
Nobody has rated this yet. Be the first!
Works
4
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy
